TABLE OF CONTENTS
Volume 32, Issue 10 (November (2) 2003)
Drug Interactions |
Peripheral Blood Stem Cells |
Chronic Myeloid Leukaemia |
Lymphoid Reconstitution |
Post-Transplant Complications |
Technical Reports |
Case Reports |
Correspondence
Mini Review
Myeloablative conditioning regimens for AML allografts: 30 years later FREE
V Gupta, H M Lazarus and A Keating
Bone Marrow Transplant 32: 969-978; doi:10.1038/sj.bmt.1704285
Drug Interactions
In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa) FREE
J Bouligand, I Boland, D Valteau-Couanet, A Deroussent, C Kalifa, O Hartmann and G Vassal
Bone Marrow Transplant 32: 979-986; doi:10.1038/sj.bmt.1704275
Peripheral Blood Stem Cells
Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry FREE
M C del Cañizo, C Martínez, E Conde, C Vallejo, S Brunet, G Sanz and M V Mateos
Bone Marrow Transplant 32: 987-992; doi:10.1038/sj.bmt.1704246
Chronic Myeloid Leukaemia
Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) FREE
F Millot, H Esperou, P Bordigoni, J-H Dalle, M Michallet, G Michel, J L Bourhis, M Kuenz, D Blaise, F Garban, E Plouvier, A Rome, J Guilhot and F Guilhot
Bone Marrow Transplant 32: 993-999; doi:10.1038/sj.bmt.1704255
Lymphoid Reconstitution
Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients FREE
P R Fallen, L McGreavey, J A Madrigal, M Potter, M Ethell, H G Prentice, A Guimarães and P J Travers
Bone Marrow Transplant 32: 1001-1014; doi:10.1038/sj.bmt.1704235
Post-Transplant Complications
Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb® immunoadsorption FREE
W Rabitsch, P Knöbl, E Prinz, F Keil, H Greinix, P Kalhs, N Worel, M Jansen, W H Hörl and K Derfler
Bone Marrow Transplant 32: 1015-1019; doi:10.1038/sj.bmt.1704264
Technical Reports
Effects of incubation temperature and time after thawing on viability assessment of peripheral hematopoietic progenitor cells cryopreserved for transplantation FREE
H Yang, J P Acker, M Cabuhat and L E McGann
Bone Marrow Transplant 32: 1021-1026; doi:10.1038/sj.bmt.1704247
Case Reports
Nonlethal transfusion associated graft-versus-host disease in a severe combined immunodeficient patient FREE
A van Royen-Kerkhof, N M Wulffraat, S S M Kamphuis, R A Brooimans, R A de Weger, M G J Tilanus, E F van Leeuwen and G T Rijkers
Bone Marrow Transplant 32: 1027-1030; doi:10.1038/sj.bmt.1704266
CO2 laser in oral graft-versus-host disease: a pilot study FREE
S Elad, R Or, M Y Shapira, A Haviv, D Galili, A A Garfunkel, M Bitan and E Kaufman
Bone Marrow Transplant 32: 1031-1034; doi:10.1038/sj.bmt.1704272
Correspondence
Dosing schedule of oral valacyclovir for prevention of herpes simplex virus FREE
M Moloney, H M Prince, J F Seymour, M Slavin and M Dooley
Bone Marrow Transplant 32: 1035; doi:10.1038/sj.bmt.1704262
